All In Biotech

Free tool

FAERS Monitor: Zepzelca

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming NDA 213702 or its brand name (Zepzelca, Lurbinectedin). Reports on generic versions are filed under their own applications.

Reports

1,169

Serious

937

80% of reports

Hospitalization

419

Death reported

286

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • death150
  • disease progression108
  • neutropenia82
  • off label use82
  • nausea70
  • thrombocytopenia60
  • fatigue56
  • febrile neutropenia47
  • anaemia45
  • asthenia45
  • vomiting43
  • injection site reaction36
  • diarrhoea31
  • acute kidney injury29
  • dyspnoea29

Reports by year received

View as table
YearReports
20131
20162
20171
20181
202054
2021126
2022244
2023249
2024180
2025161
2026150

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,052,990 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
disease progressionSignal10816.413.71,558
febrile neutropeniaSignal4712.89.6499
neutropeniaSignal8210.98.8728
thrombocytopeniaSignal609.77.5459
injection site reactionSignal369.46.8263
anaemiaSignal454.23.2109
acute kidney injurySignal293.42.447
deathSignal1503.12.7225
astheniaSignal452.21.627
off label use821.71.423
vomiting431.61.210
nausea701.61.315
fatigue561.31.04
dyspnoea290.90.60
diarrhoea310.90.61

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.